[R01] FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.
Ente: National Institute on Aging
Scadenza: 2030-07-31
Importo max: 4.923.453 EUR
Paese: US
Descrizione
Project Summary
Alzheimer's disease (AD) is the most common type of dementia characterized by memory impairment and
alteration of diverse cognitive abilities. It is a complex and multifactorial disease involving various genetic and
environmental risk factors that lead to the development of two hallmark pathologies: β-amyloid (Aβ)
oligomers/fibrils/plaques and tau aggregates/tangles followed by inflammation and severe neurodegeneration.
The modern version of the "amyloid cascade" hypothesis suggests that Aβ oligomer formation is critical for
initiating tau pathology and downstream pathological processes, including inflammation, oxidative stress, and
synaptic and neuronal loss, while the accumulation of pathological tau is directly correlated with the disease
progression and severity. Therefore, the development of potential therapies for AD has been mainly focused on
reducing pathological Aβ or Tau and, more recently, on inflammation associated with accumulating these
pathological molecules in the brain. Although results from active and passive immunotherapy in AD patients and
MCI subjects are promising, thus far collectively, they showed only little benefit of the cognitive or functional
outcomes, likely because the treatment was initiated too late. Therefore, currently, AD research shifts from the
treatment to the prevention of disease, and it coincides with our long-standing tenet that a safe and immunogenic
preventive Aβ and/or tau vaccines should be initiated in cognitively unimpaired people at risk of MCI due to AD
(preclinical stage). Passive mAb-based immunotherapy initiated in cognitively unimpaired people at risk of AD,
however, is impractical due to the complexity, cost, and need for frequent (weekly/monthly) administrations of
very high doses of antibodies. By comparison, safe and immunogenic active vaccines are suitable candidates
for preventing the accumulation of Aβ and/or tau pathologies and delaying the onset of symptoms in people at
risk. Here we propose to evaluate the safety and immunogenicity of the first-in-human MultiTEP-based Tau
vaccine, AV-1980R/A, targeting the Phosphatase Activating Domain (PAD) exposed in pathological tau
in volunteers with preclinical AD selected by a novel plasma test, PrecivityAD2™ Amyloid Probability Score 2
(APS2) ≥ 47.5 and absent cognitive impairment as evidenced by CDR = 0, MMSE > 26, and WMS LM II > 6.
Notably, our vaccine strategy differs from all previous or current vaccines tested in clinical trials, as our approach
is based on the very immunogenic and proprietary MultiTEP platform designed for human use and aimed to (i)
overcome self-tolerance by inducing Th cell responses to MultiTEP, but not to self-tau epitopes; (ii) diminish
variability of immune responses due to HLA diversity in humans; (iii) augment pathological tau-specific antibody
production through activation of both naïve and pre-existing memory Th cells, especially beneficial for the elderly
with immunosenescence. This clinical
Istituzione: INSTITUTE FOR MOLECULAR MEDICINE
PI: Michael G Agadjanyan, James E Galvin, LON S SCHNEIDER, Duygu Tosun-Turgut
Progetto: 5R01AG092949-02
Settori: National Institute on Aging
Vai al bando originale
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.